Gollapelli Krishna K, Krizan Ivan, Bhoopal Bhuvanachandra, Damuka Naresh, Moriarty Carson, Miller Mack, Sai Kiran K Solingapuram, Gould Robert W
Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Department of Translational Neuroscience, Center for Addiction Research, Wake Forest University School of Medicine, 115 South Chestnut St, Winston-Salem, NC, 27101, USA.
Pharmacol Rep. 2025 Apr;77(2):532-541. doi: 10.1007/s43440-025-00695-9. Epub 2025 Jan 14.
Cocaine Use Disorder (CUD) remains a significant problem in the United States, with high rates of relapse and no present FDA-approved treatment. The acetylcholine neurotransmitter system, specifically through modulation of muscarinic acetylcholine receptor (mAChR) function, has shown promise as a therapeutic target for multiple aspects of CUD. Enhancement of the M mAChR subtype via positive allosteric modulation has been shown to inhibit the behavioral and neurochemical effects of cocaine across several rodent models of CUD. However, it is unclear how cocaine exposure affects M mAChR expression or distribution.
To evaluate the effects of cocaine self-administration on M mAChR availability using [C]MK-6884 in vivo PET imaging in rats that self-administered cocaine (cocaine SA) or sucrose pellets (control).
Sprague-Dawley rats self-administered cocaine or sucrose pellets for 15 days under 2-h or 4-h sessions followed by PET imaging with [C]MK-6884, a radiolabeled M selective positive allosteric modulator to determine the effects of cocaine on [C]MK-6884 standard uptake values with cerebellum as reference (SUVr).
Cumulative cocaine intake ranged between 324 and 776 mg/kg. Cocaine self-administration was associated with significantly lower [C]MK-6884 SUVrs in the cortex, hippocampus, and striatum compared to cocaine-naive rats, with a negative correlation between radiotracer SUVrs and cocaine intake in the hippocampus.
These results suggest that cocaine self-administration decreases M mAChR availability, providing further support for pursuing activation/enhancement of M mAChR function as a viable pharmacotherapeutic approach for CUD.
可卡因使用障碍(CUD)在美国仍然是一个重大问题,复发率高且目前没有获得美国食品药品监督管理局(FDA)批准的治疗方法。乙酰胆碱神经递质系统,特别是通过调节毒蕈碱型乙酰胆碱受体(mAChR)功能,已显示出有望成为治疗CUD多个方面的靶点。通过正向变构调节增强M型mAChR亚型已被证明在多种CUD啮齿动物模型中可抑制可卡因的行为和神经化学作用。然而,尚不清楚可卡因暴露如何影响M型mAChR的表达或分布。
使用[C]MK-6884在体内PET成像评估可卡因自我给药对自行给予可卡因(可卡因自我给药组)或蔗糖颗粒(对照组)的大鼠M型mAChR可用性的影响。
斯普拉格-道利大鼠在2小时或4小时的时间段内自行给予可卡因或蔗糖颗粒,持续15天,随后用[C]MK-6884进行PET成像,[C]MK-6884是一种放射性标记的M型选择性正向变构调节剂,以小脑为参考来确定可卡因对[C]MK-6884标准摄取值(SUVr)的影响。
累积可卡因摄入量在324至776mg/kg之间。与未接触过可卡因的大鼠相比,可卡因自我给药组大鼠的皮质、海马体和纹状体中[C]MK-6884的SUVr显著降低,放射性示踪剂SUVr与海马体中可卡因摄入量之间呈负相关。
这些结果表明,可卡因自我给药会降低M型mAChR的可用性,为将激活/增强M型mAChR功能作为CUD的一种可行药物治疗方法提供了进一步支持。